We further detected p-GSK3β-S9 (inactivated form) through Western blotting and found that its level was increased with GK treatment, indicating that GSK3β promotes AD pathogenesis as a therapeutic target of GF. The gene discussed is GSK3B; the disease is Alzheimer disease.